Gangliosides-glycosphingolipids in mammalian cells -have a role in promoting nerve repair by increasing collateral sprouting.' Trials of exogenous gangliosides as adjuvant treatment for various neuropathies, however, either have had gross methodological deficiencies or have shown lack of clinical improvement.2 In 1989 Cronassial, a ganglioside prepared from bovine brain, was withdrawn in Germany after reports of GuillainBarre syndrome and amyotrophic lateral sclerosis in patients given it. ' The Spanish national drug surveillance system receives reports from physicians and hospital pharmacists, covers three quarters of the general population, and has over 18 000 reports in its database. We review the 17 cases of Guillain-Barre syndrome and other acute motor polyneuropathy associated with use of gangliosides reported up to 29 February 1992.
Present series and results
All 17 patients (10 women) had received fixed dose bovine gangliosides containing GM1 (17-25%), GDIa (36-46%), GDlb (12-18%), and GTlb (14-22%) (Nevrotal). Three had died (table) . The 17 cases had been reported to six different regional centres, and in all the diagnosis had been confirmed by a neurologist. Fifteen patients had started Nevrotal within four weeks before the diagnosis. In the other two the date was unknown, though it preceded the acute motor polyneuropathy.
In eight patients the clinical indication for gangliosides either was not related to any prodrome of Guillain-Barre syndrome or acute motor polyneuropathy or had been present for too long to be interpreted as a prodrome. These cases are listed as "probable" in the table. One patient had a cold and two patients an episode of diarrhoea in the month before diagnosis. Electromyography reports were available in all eight cases. In the remaining nine cases we could not exclude the indication for using gangliosides as a prodrome. We refer to these cases as "possible."
In 14 cases the indications for using gangliosides were not among those approved in Spain (that is, diabetic and post-traumatic neuropathies). Nine patients had taken other drugs with Nevrotal (analgesic/anti-inflammatory drugs, antihypertensive agents, vitamins). Overall, 13 patients were partially or completely recovered from the complication within three months. Of the others, three died and one was continuing with gangliosides.
Albuminocytological dissociation in cerebrospinal fluid was present in seven patients. Serological tests and cerebrospinal fluid cultures for common infective agents in Guillain-Barre syndrome (Brucella, Campylobacter, Mycoplasma, herpes simplex virus, hepatitis B virus) gave negative results in all nine cases for which this information was available. Lyme disease may cause similar neuropathies.5 Antibodies to Borrelia were sought unsuccessfully in three patients.
Comment
Assessing a causal relation between exposure to bovine gangliosides and acute motor polyneuropathy is problematical. Firstly, the symptoms of these conditions are heterogeneous and the time courses unknown. Hence it may be difficult to establish whether the drug was administered before the onset of neurological disturbances or if it was prescribed to treat early symptoms. Secondly, antecedent infections by various agents are reportedly associated with Guillain-Barre syndrome. However, the agents which might be involved and how infection triggers the disease are unknown. We know even less about the aetiology of acute motor polyneuropathy. It is difficult to support the lack of a causal relation in some cases solely on the basis of an antecedent of the common cold, flu, or diarrhoea several days before the onset of symptoms.
A historical cohort study aimed at determining the Clinicalfeatures of 17 cases ofacuite mizotor polynieuiropathy associated with exposure to gangliosides reported to Spanish drug surveillance system BMJ VOLUME 305 safety of bovine gangliosides was carried out in Ferrara, Italy. No case of Guillain-Barre syndrome was found, but the sample was small (18 945 person years) given the incidence of the syndrome (0-6 to 19/100000 population yearly).' Studying the aetiology of conditions whose pathophysiology and clinical course are poorly understood may be difficult and controversial. Formal epidemiological studies in this setting, however, can be justified only if the efficacy of the suspected causal drug is clearly delineated. This is not the case with gangliosides, and hence the Spanish National Commission of Pharmacovigilance has proposed their withdrawal.
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Methods and results
We studied all incident cases of lung cancer (ICD (ninth revision) code 162) and breast cancer (ICD (ninth revision) code 174) that occurred during 1975-90 in women resident in the City of Glasgow local government district (population in 1990,689 000). Incidence rates were standardised for age against the population for 1981. Population data were obtained from the annual reports of the registrar general for Scotland.
The age standardised incidence of lung cancer increased from 52/100000 in 1975 to 115/100000 in 1990. That of breast cancer increased slightly from 97/100000 in 1975 to 105/100000 in 1990 (figure). Women aged 55-64 were the youngest group in whom the incidence of lung cancer increased. The steepest increase occurred in women aged 65-74: in these women the rate for 1990 was 3-6 times that for 1975 (p < 0001). Women born during 1915-29 experienced the highest rates of lung cancer. The incidence for a given age progressively decreased for women born after 1930. The median age at diagnosis of lung cancer was 62 for women born during 1915-29.
Ratios of mortality to incidence for breast and lung cancer in Glasgow changed little between 1975 and 1990. Registrations based solely on death certification data showed a similar pattern for both sites over the period.
Comment
The increase in the incidence of lung cancer is unlikely to be due to bias in the registration of cancer in Glasgow. It is also unlikely to be an artefact of lung cancers being registered without histological verification. A case-control study carried out in westem Scotland during 1976-81 compared exposure to cigarette smoke for patients with lung cancer with and without histological verification and showed no difference in the relative risk. Glasgow, 1975-90 
